首页> 外文期刊>Therapeutic Drug Monitoring >Therapeutic Drug Monitoring of Pentobarbital: Experience at an Academic Medical Center
【24h】

Therapeutic Drug Monitoring of Pentobarbital: Experience at an Academic Medical Center

机译:戊巴比妥的治疗药物监测:在学术医学中心的经验

获取原文
获取原文并翻译 | 示例
       

摘要

Background:Pentobarbital is used for management of intractable seizures and for reducing elevated intracranial pressure. Dosing of pentobarbital can be aided by therapeutic drug monitoring (TDM). There is no commercially available automated assay for measurement of pentobarbital serum/plasma concentrations; consequently, chromatography-based assays are often used.Methods:Pentobarbital TDM was studied over a 14-year period at an academic medical center. 154 patients (94 adult, 60 pediatric) were identified who had pentobarbital levels ordered at least once during a hospital encounter. Chart review included patient diagnosis, indication for pentobarbital therapy, recent or concomitant medication with other barbiturates, patient disposition, organ donation, pentobarbital dosing changes, and neurosurgical procedures. Pentobarbital serum/plasma concentrations were determined on an automated clinical chemistry platform with a laboratory-developed test adapted from a urine barbiturates immunoassay.Results:Chart review showed therapeutic use of pentobarbital generally consistent with previously published literature. The most common errors observed involved confusion in barbiturate names (eg, mix-up of pentobarbital and phenobarbital in test ordering or in provider notes) that seemed to have minimal impact on TDM effectiveness, with pentobarbital serum/plasma concentrations generally within target ranges. The laboratory-developed pentobarbital immunoassay showed cross-reactivity with phenobarbital and butalbital that was eliminated by alkaline and heat pretreatment. The immunoassay was linear to 20 mcg/mL and correlated closely with gas chromatography-mass spectrometry measurements at a reference laboratory.Conclusions:Pentobarbital TDM can be performed by immunoassay on an automated clinical chemistry platform, providing an alternative to chromatography-based methods. Confusion in barbiturate names is common, especially pentobarbital and phenobarbital.
机译:背景:戊巴比妥用于治疗顽固性癫痫发作并降低颅内压升高。戊巴比妥的剂量可以通过治疗药物监测(TDM)来辅助。目前尚无用于测量戊巴比妥血清/血浆浓度的市售自动测定法。方法:对苯巴比妥TDM在一个学术医学中心进行了长达14年的研究。确认有154名患者(94名成人,60名儿科患者)在医院遭遇期间至少点过一次戊巴比妥水平。图表审查包括患者诊断,戊巴比妥治疗的适应症,近期或与其他巴比妥类药物同时用药,患者处置,器官捐赠,戊巴比妥剂量变化和神经外科程序。戊巴比妥血清/血浆浓度是在自动临床化学平台上通过实验室开发的,根据尿巴比妥酸盐免疫测定法测定的试验确定的。结果:图表回顾表明戊巴比妥的治疗用途与以前发表的文献基本一致。观察到的最常见错误涉及巴比妥类药物名称的混淆(例如,在测试订单中或提供者说明中戊巴比妥和苯巴比妥的混合)对TDM有效性的影响似乎最小,戊巴比妥的血清/血浆浓度通常在目标范围内。实验室开发的戊巴比妥免疫测定法显示与苯巴比妥和丁比妥具有交叉反应性,而碱性和热预处理消除了交叉反应性。免疫测定呈线性至20 mcg / mL,并与参考实验室的气相色谱-质谱分析法密切相关。结论:可以通过在自动化临床化学平台上进行免疫测定来进行戊巴比妥TDM,这是基于色谱法的替代方法。巴比妥类药物的名称很常见,尤其是戊巴比妥和苯巴比妥。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号